Douglas Huseby is a researcher and program manager for ENABLE-2 at the University of Uppsala in Uppsala, Sweden. His research career has focused on various topics in bacterial genetics, including evolution, mechanisms of antibiotic resistance, and the development of novel antibiotics.
Since 2014, he has worked on the EU’s Innovative Medicines Initiative New Drugs 4 Bad Bugs ENABLE program, as well as its Swedish follow-up, ENABLE-2. These programs have facilitated connections between early-stage antibiotic development programs and experimental resources in academia, as well as expertise from pharmaceutical companies, to advance their projects. In these programs, Douglas has worked on many antibiotic discovery and development projects, helping to identify the mechanism of action and resistance mechanisms to novel antimicrobial compounds.